The innovative evolution of cancer gene and cellular therapies

被引：0

作者：

P Lam

G Khan

R Stripecke

K M Hui

N Kasahara

K-W Peng

B-A Guinn

机构：

[1] National Cancer Centre,Division of Cellular and Molecular Research

[2] University of Bedfordshire,Department of Life Sciences

[3] Lymphatic Cell Therapy Program,Department of Biochemistry

[4] Excellence Cluster for Regenerative Biology (REBIRTH),Department of Medicine

[5] Hannover Medical School,Department of Molecular Medicine

[6] Yong Loo Lin School of Medicine,Department of Haematological Medicine

[7] National University of Singapore,undefined

[8] Program in Cancer and Stem Cell Biology,undefined

[9] Duke-NUS Graduate Medicinal School,undefined

[10] David Geffen School of Medicine,undefined

[11] University of California Los Angeles,undefined

[12] Mayo Clinic,undefined

[13] Cancer Sciences Unit,undefined

[14] Somers Cancer Sciences Building,undefined

[15] Southampton University Hospitals,undefined

[16] University of Southampton,undefined

[17] King’s College London School of Medicine,undefined

来源：

Cancer Gene Therapy | 2013年 / 20卷

关键词：

stem cells; immunotherapy; cancer research;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

We provide an overview of the latest developments in cancer gene therapy—from the bench to early-stage clinical trials. We describe the most recent work of worldwide teams including experienced scientists and clinicians, reflecting the recent emergence of gene therapy from the ‘Valley of Death’. The treatment efficacy of clinical gene therapy has now been shown in a number of diseases including cancer and we are observing a renewed interest by big pharmaceutical and biotechnology companies most obviously demonstrated by Amgen’s acquisition of Biovex for up to USD$1 billion. There is an opportunity to be cautiously hopeful regarding the future of gene therapy in the clinic and we review here some of the most recent progress in the field.

引用

页码：141 / 149

页数：8

共 50 条

[41] The use of innovative payment mechanisms for gene therapies in Europe and the USA
Jorgensen, Jesper
Kefalas, Panos
REGENERATIVE MEDICINE, 2021, 16 (04) : 405 - 422
[42] The Landscape of Adoptive Cellular Therapies in Ovarian Cancer
Davis, Lucy
Miller, Rowan E.
Wong, Yien Ning Sophia
CANCERS, 2023, 15 (19)
[43] Neonatal cellular and gene therapies for mucopolysaccharidoses: the earlier the better?
Tomatsu, Shunji
Azario, Isabella
Sawamoto, Kazuki
Pievani, Alice Silvia
Biondi, Andrea
Serafini, Marta
JOURNAL OF INHERITED METABOLIC DISEASE, 2016, 39 (02) : 189 - 202
[44] Trojan horse at cellular level for tumor gene therapies
Collet, Guillaume
Grillon, Catherine
Nadim, Mahdi
Kieda, Claudine
GENE, 2013, 525 (02) : 208 - 216
[45] Cellular and gene therapies .1. Regulatory health
Chew, NJ
BIOPHARM-THE TECHNOLOGY & BUSINESS OF BIOPHARMACEUTICALS, 1995, 8 (08): : 22 - &
[46] Cellular and gene therapies face a manufacturing capacity crunch
Rader, Ronald A.
Pharmaceutical Technology, 2020, 44 (10) : 56 - 59
[47] Cellular and Gene Therapies Face a Manufacturing Capacity Crunch
Rader, Ronald A.
BIOPHARM INTERNATIONAL, 2020, 33 (09) : 46 - 49
[48] REGULATORY REVIEW OF CELLULAR AND GENE THERAPIES - AN OVERVIEW OF THE PROCESS
MARTI, GE
BAUER, S
PURI, RK
NOGUCHI, PD
TRANSFUSION SCIENCE, 1994, 15 (04): : 323 - 329
[49] Cellular and gene therapies .2. Off the RAC
Chew, NJ
BIOPHARM-THE TECHNOLOGY & BUSINESS OF BIOPHARMACEUTICALS, 1996, 9 (01): : 20 - &
[50] Innovative therapies
Stawowy, P.
Fleck, E.
KARDIOLOGE, 2011, 5 (06): : 409 - 410

← 1 2 3 4 5 →